Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

Safdar Khan; Vanessa Anne Concina; Douglas Schneider; Philip Westgate; Susana Arriagada; Henrietta Bada

doi:10.1002/ppul.24610

Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

Safdar Khan
, Vanessa Anne Concina
, Douglas Schneider
, Philip Westgate
, Susana Arriagada
, Henrietta Bada

Producción científica: Article › revisión exhaustiva

19 Citas (Scopus)

Resumen

Objective: The objective of the study was to determine the clinical utility of brain natriuretic peptide (NT-proBNP) for prediction of moderate to severe bronchopulmonary dysplasia (BPD). We hypothesized that elevated NT-proBNP levels at 4 weeks of postnatal age may predict the severity of BPD in preterm infants. Study Design: The study design was a prospective observational study. The research team enrolled and followed a cohort of 70 infants with gestational age less than or equal to 30 weeks. The plasma NT-proBNP levels were measured at the postnatal day 28th. We further followed and categorized infants into two groups. Infants with no or mild BPD (Group 1) and infants with moderate or severe BPD (Group 2). We compared plasma NT-proBNP levels at 28th day of postnatal life between Groups 1 and 2. The difference in NT-proBNP levels on day 28th between groups was used to predict the severity of BPD. Results: Plasma NT-proBNP was significantly elevated in Group 2 compared with Group 1, median (IQR) of 845 pg/mL (553, 1632) compared with 726 pg/mL (391, 923), P = 0.02. NT-proBNP had a fair predictive accuracy (C statistics of 0.68) to determine moderate to severe BPD. Conclusion: NT-proBNP may be a useful biomarker in conjunction with clinical factors as a predictor of severe BPD. For future directions, the trend of NT-proBNP in infants with BPD may have clinical significance in monitoring of the disease.

Idioma original	English
Páginas (desde-hasta)	376-382
Número de páginas	7
Publicación	Pediatric Pulmonology
Volumen	55
N.º	2
DOI	https://doi.org/10.1002/ppul.24610
Estado	Published - feb 1 2020

Nota bibliográfica

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Financiación

The project described was supported by the National Center for Advancing Translational Sciences, UL1TR000117, the Dean of the College of Medicine, University of Kentucky, and the Kentucky Children's Hospital (Children's Miracle Network grant). The authors thank the NICU nurses, research nurses, and respiratory therapists, the fellows, attending neonatologists and the parents and families at Kentucky Children's Hospital. The authors thank Ms. Nichole Park for her assistance in the NT‐proBNP assays. This project was presented at the 2016 Pediatric Academic Society Conference at Baltimore, MD. The National Center for Advancing Translational Sciences, NIH (grant number UL1TR000117), and Children's Miracle Network supported this project. The project described was supported by the National Center for Advancing Translational Sciences, UL1TR000117, the Dean of the College of Medicine, University of Kentucky, and the Kentucky Children's Hospital (Children's Miracle Network grant). The authors thank the NICU nurses, research nurses, and respiratory therapists, the fellows, attending neonatologists and the parents and families at Kentucky Children's Hospital. The authors thank Ms. Nichole Park for her assistance in the NT-proBNP assays. This project was presented at the 2016 Pediatric Academic Society Conference at Baltimore, MD. The National Center for Advancing Translational Sciences, NIH (grant number UL1TR000117), and Children's Miracle Network supported this project.

Financiadores	Número del financiador
Children's Miracle Network Hospitals
Kentucky Children's Hospital
Department of Paediatrics and NICU
Pediatric Academic Society Conference at Baltimore
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)	UL1TR000117
National Center for Advancing Translational Sciences (NCATS)
University of Kentucky

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Acceder al documento

10.1002/ppul.24610

Otros archivos y enlaces

Citar esto

@article{e92b690d7b9c47ff81273b4fdda65023,

title = "Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants",

abstract = "Objective: The objective of the study was to determine the clinical utility of brain natriuretic peptide (NT-proBNP) for prediction of moderate to severe bronchopulmonary dysplasia (BPD). We hypothesized that elevated NT-proBNP levels at 4 weeks of postnatal age may predict the severity of BPD in preterm infants. Study Design: The study design was a prospective observational study. The research team enrolled and followed a cohort of 70 infants with gestational age less than or equal to 30 weeks. The plasma NT-proBNP levels were measured at the postnatal day 28th. We further followed and categorized infants into two groups. Infants with no or mild BPD (Group 1) and infants with moderate or severe BPD (Group 2). We compared plasma NT-proBNP levels at 28th day of postnatal life between Groups 1 and 2. The difference in NT-proBNP levels on day 28th between groups was used to predict the severity of BPD. Results: Plasma NT-proBNP was significantly elevated in Group 2 compared with Group 1, median (IQR) of 845 pg/mL (553, 1632) compared with 726 pg/mL (391, 923), P = 0.02. NT-proBNP had a fair predictive accuracy (C statistics of 0.68) to determine moderate to severe BPD. Conclusion: NT-proBNP may be a useful biomarker in conjunction with clinical factors as a predictor of severe BPD. For future directions, the trend of NT-proBNP in infants with BPD may have clinical significance in monitoring of the disease.",

keywords = "biomarkers, bronchopulmonary dysplasia",

author = "Safdar Khan and Concina, \{Vanessa Anne\} and Douglas Schneider and Philip Westgate and Susana Arriagada and Henrietta Bada",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = feb,

day = "1",

doi = "10.1002/ppul.24610",

language = "English",

volume = "55",

pages = "376--382",

number = "2",

}

TY - JOUR

T1 - Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

AU - Khan, Safdar

AU - Concina, Vanessa Anne

AU - Schneider, Douglas

AU - Westgate, Philip

AU - Arriagada, Susana

AU - Bada, Henrietta

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Objective: The objective of the study was to determine the clinical utility of brain natriuretic peptide (NT-proBNP) for prediction of moderate to severe bronchopulmonary dysplasia (BPD). We hypothesized that elevated NT-proBNP levels at 4 weeks of postnatal age may predict the severity of BPD in preterm infants. Study Design: The study design was a prospective observational study. The research team enrolled and followed a cohort of 70 infants with gestational age less than or equal to 30 weeks. The plasma NT-proBNP levels were measured at the postnatal day 28th. We further followed and categorized infants into two groups. Infants with no or mild BPD (Group 1) and infants with moderate or severe BPD (Group 2). We compared plasma NT-proBNP levels at 28th day of postnatal life between Groups 1 and 2. The difference in NT-proBNP levels on day 28th between groups was used to predict the severity of BPD. Results: Plasma NT-proBNP was significantly elevated in Group 2 compared with Group 1, median (IQR) of 845 pg/mL (553, 1632) compared with 726 pg/mL (391, 923), P = 0.02. NT-proBNP had a fair predictive accuracy (C statistics of 0.68) to determine moderate to severe BPD. Conclusion: NT-proBNP may be a useful biomarker in conjunction with clinical factors as a predictor of severe BPD. For future directions, the trend of NT-proBNP in infants with BPD may have clinical significance in monitoring of the disease.

AB - Objective: The objective of the study was to determine the clinical utility of brain natriuretic peptide (NT-proBNP) for prediction of moderate to severe bronchopulmonary dysplasia (BPD). We hypothesized that elevated NT-proBNP levels at 4 weeks of postnatal age may predict the severity of BPD in preterm infants. Study Design: The study design was a prospective observational study. The research team enrolled and followed a cohort of 70 infants with gestational age less than or equal to 30 weeks. The plasma NT-proBNP levels were measured at the postnatal day 28th. We further followed and categorized infants into two groups. Infants with no or mild BPD (Group 1) and infants with moderate or severe BPD (Group 2). We compared plasma NT-proBNP levels at 28th day of postnatal life between Groups 1 and 2. The difference in NT-proBNP levels on day 28th between groups was used to predict the severity of BPD. Results: Plasma NT-proBNP was significantly elevated in Group 2 compared with Group 1, median (IQR) of 845 pg/mL (553, 1632) compared with 726 pg/mL (391, 923), P = 0.02. NT-proBNP had a fair predictive accuracy (C statistics of 0.68) to determine moderate to severe BPD. Conclusion: NT-proBNP may be a useful biomarker in conjunction with clinical factors as a predictor of severe BPD. For future directions, the trend of NT-proBNP in infants with BPD may have clinical significance in monitoring of the disease.

KW - biomarkers

KW - bronchopulmonary dysplasia

UR - https://www.scopus.com/pages/publications/85076919761

UR - https://www.scopus.com/pages/publications/85076919761#tab=citedBy

U2 - 10.1002/ppul.24610

DO - 10.1002/ppul.24610

M3 - Article

C2 - 31869001

AN - SCOPUS:85076919761

SN - 8755-6863

VL - 55

SP - 376

EP - 382

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

IS - 2

ER -

Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto